Innovating Cancer Care, By Design

Mural Oncology immunotherapy employee sitting at desk smiling and folded hands

Our Mission

Unlocking the value of immunotherapy for more patients

At Mural Oncology we are leveraging our industry-leading protein engineering platform to reimagine cytokine-based immunotherapies for the treatment of cancer. Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most: living.

white paint stroke bottom

We are

Devoted to advancing the field of cancer science

We leverage our expertise in cytokine biology, immune cell modulation and our unmatched protein engineering capabilities to develop first- and best-in-class immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Woman using lab equipment in a lab setting studying cancer immunotherapy options
Digital scan of a cancerous tumor before immunotherapy
microscopic scan of a cancerous tumor before immunotherapy
White paint stroke top


Our Pipeline

We are developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available today.

Nemvaleukin Alfa - IL-2 Variant

Indication Discovery Preclinical Phase 1 Phase 2 Phase 3

  • Platinum-Resistant Ovarian Cancer ARTISTRY-7
    Phase 3
  • Mucosal Melanoma ARTISTRY-6, Cohort 2
    Phase 2
  • Cutaneous Melanoma ARTISTRY-6, Cohorts 3 & 4
    Phase 2
  • Advanced Solid Tumors ARTISTRY-3
    Phase 1

Last updated: March 2024

white paint stroke bottom


Mural Oncology News

Learn about our latest milestones and achievements.

Mural Oncology logo over water color themed background
calendar icon

June 5, 2024

Mural to Present and Host 1×1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference

>> Read the Press Release
Mural Oncology logo over water color themed background
calendar icon

May 23, 2024

Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting

>> Read the Press Release
calendar icon

May 14, 2024

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

>> Read the Press Release

Are you inspired to make a difference for people living with cancer?

Bring your passion and talent to help us achieve our mission. Visit our Careers page to learn more about what it's like to be part of Mural Oncology and explore current opportunities to join our team.

female mural employee smiling in office


Our Clinical Trials

Clinical trials are currently underway to explore the safety and efficacy of nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy, in difficult-to-treat cancers with high unmet need.

Dropper seen adding liquid to vial.
Artistry logo


ARTISTRY-7 is enrolling adult patients with advanced or metastatic (cancer that has spread) epithelial ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based therapy.

Lab science research glass items adding drop to one of several test tubes.
Artistry logo


ARTISTRY-6 is enrolling adult patients with advanced or inoperable cutaneous and mucosal metastatic melanoma who have previously received anti-PD-[L]-1 therapy.

Needle syringe in a vial.
Artistry logo


ARTISTRY-3 is a phase 2 study evaluating clinical and immunologic activity with less frequent IV dosing in people with advanced solid tumors.

I am motivated and inspired by knowing that what I'm doing in the laboratory will have a positive impact for communities and patients that are struggling with cancer. Knowing that I can make a difference is really powerful and rewarding.

Pinar Gurel, Research